Dostarlimab Achieves Complete Response in Rare SMARCA4-Deficient Metastatic Uterine Sarcoma Case
A patient with metastatic SMARCA4-deficient undifferentiated uterine sarcoma achieved a 42-month complete response following dostarlimab therapy.
A patient with metastatic SMARCA4-deficient undifferentiated uterine sarcoma achieved a 42-month complete response following dostarlimab therapy.
A review evaluates combination strategies designed to enhance immune checkpoint inhibitor efficacy in immunosuppressive microsatellite stable colorectal cancer.
A comprehensive clinical review establishes a three-strata framework categorizing gastrointestinal cancers by immunogenicity to guide chemotherapy-free regimens, synergistic combinations, and ...
A machine learning model combining PD-L1 expression, tumor mutational burden, and clinical factors demonstrated superior discrimination over traditional nomograms in ...
Researchers developed a 24-gene multi-omics signature in clear cell renal cell carcinoma that maps spatial immune exclusion and outperforms traditional ...
Integrated multi-omics analyses identified Peroxiredoxin 4 as an independent prognostic biomarker linked to M2-like macrophage features and poor survival in ...
Whole-exome sequencing of paired tumor and normal tissues from eight cervical cancer patients treated with immunotherapy in China revealed striking ...
A retrospective cohort analysis found that specific germline mismatch repair gene alterations do not significantly affect progression-free survival in patients ...
A systematic pan-cancer analysis and laboratory validation reveal that Claudin-18 promotes cellular proliferation in liver and colorectal cancers while correlating ...
Clonal hematopoiesis mutations in circulating blood cells are significantly linked to neoadjuvant chemotherapy resistance, impaired cytotoxic T cell infiltration, and ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine